San Diego, CA, January 25, 2008 — Phenomix Corporation announced today that the company has filed a registration statement with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by Phenomix.

Morgan Stanley & Co. Incorporated and Credit Suisse (USA) LLC will serve as joint book-running managers for the offering, for which Oppenheimer & Co. and Pacific Growth Equities, LLC are acting as co-managers.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained by contacting: Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, Attention: Prospectus Department or by email at [email protected]; or Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, New York, New York 10010-3629 (Telephone number 1-800-221-1037).

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Phenomix Corporation
Phenomix is a drug discovery and development company building a portfolio of internally discovered, novel therapeutics for the treatment of major human diseases. Phenomix' lead program, PHX1149, is a DPP4 inhibitor in Phase 2b clinical trials as a once daily oral treatment for Type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C infections through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California. For more information, visit

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.